MedTrace Logo

Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients

NCT00467311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2008-05-08

No results posted yet for this study

Summary

Hypothesis:

Cystatin C compared with creatinine is a better and earlier marker of contrast-induced nephropathy in high and intermedium risk cardiac catheterization patients.

Primary Objective:

Establish if Cystatin C is superior detecting contrast-induced nephropathy than creatinine in high and intermedium risk cardiac catheterization patients.

Conditions

  • Contrast Induced Nephropathy
  • Acute Renal Failure

Sponsors & Collaborators

  • National Heart Institute, Mexico

    lead OTHER_GOV

Principal Investigators

  • Jhonathan L Uribe-González, MD, MSc · Ignacio Chávez National Institute of Cardiology

  • Jorge G Hernández, MD, FSCAI · Ignacio Chávez National Institute of Cardiology

  • Marco A Martínez-Rios · Ignacio Chávez National Institute of Cardiology

  • Marco A Peña-Duque, MD · Ignacio Chávez National Institute of Cardiology

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467311 on ClinicalTrials.gov